Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension

Pulmonary Circulation

Volumn 5, Issue 1, 2015, Pages 101-116

  Al Husseini, Ayser ^a   Kraskauskas, Donatas ^a   Mezzaroma, Eleanora ^a   Nordio, Andrea ^a   Farkas, Daniela ^a   Drake, Jennifer I ^a   Abbate, Antonio ^a   Felty, Quentin ^b   Voelkel, Norbert F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Capillary rarefaction; Chronic hypoxia; MAZ51; Right heart failure; SFlt 1; Sugen 5416; VEGF isoforms; VEGF receptor 3

Indexed keywords

EID: 85026337409     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/679704     Document Type: Review

References (74)

1. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012;40(6):1555-1565.
2. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54 (suppl):S10-S19.
3. Perros F, Dorfmuller P, Montani D, Hammad H, Waelput W, Girerd B, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185(3):311-321.
4. Colvin KL, Cripe PJ, Ivy DD, Stenmark KR, Yeager ME. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. Am J Respir Crit Care Med 2013;188(9):1126-1136.
5. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013;5(200):200ra117.
6. Chow K, Fessel JP, Ihida-Stansbury K, Schmidt EP, Gaskill C, Alvarez D, et al. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. Pulm Circ 2013;3(1):31-49.
7. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122(12):4306-4313.
8. Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013;123(8):3600-3613.
9. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 2002;80(4):269-274.
10. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121(25):2747-2754.
11. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc- Mahon G, Waltenberger J, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death- dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15(2):427-438.
12. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, et al. Critical role for the advanced glycation endproducts receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2013;2(1):e005157
13. De Bock K, Georgiadou M, Carmeliet P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab 2013;18 (5):634-647
14. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 2012;484(7392):110-114
15. Arany Z, Foo S-Y, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 2008;451(7181):1008-1012
16. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014;141(2):117-124
17. Zhuang G, Yu K, Jiang Z, Chung A, Yao J, Ha C, et al. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal 2013;6(271):ra25
18. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12(10):699-709
19. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999;247(2):495-504
20. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-395
21. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005;11(11):1188-1196
22. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006;8(11):1223-1234
23. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012;2(7):a006502
24. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS ONE 2011;6(9):e25668
25. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene- Stewart L, Kasahara Y, et al. Expression of angiogenesisrelated molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195(3):367-374
26. Hewett PW, Murray JC. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 1996;221(3):697-702
27. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998;273(14):8413-8418
28. Janer J, Lassus P, Haglund C, Paavonen K, Alitalo K, Andersson S. Pulmonary vascular endothelial growth factor- C in development and lung injury in preterm infants. Am J Respir Crit Care Med 2006;174(3):326-330
29. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454(7204):656-660
30. Datar SA, Johnson EG, Oishi PE, Johengen M, Tang E, Aramburo A, et al. Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow. AmJ Physiol Lung Cell Mol Physiol 2012;302(6):L530-L540
31. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 2010; 17(4):253-261
32. Kirkin V, Thiele W, Baumann P, Mazitschek R, Rohde K, Fellbrich G, et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer 2004;112(6):986-993
33. Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, et al. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci 2008;65(17):2740-2751
34. Gomez-Arroyo J, Szczepanek K, Syed A, Farkas L, Farkas D, Kraskauskas D, et al. Metabolic remodeling in right heart failure is associated with abnormal mitochondrial biogenesis. Am J Respir Crit Care Med 2012;185:A3455
35. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, hau VQ, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010:182(5):652-660
36. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93(6):2576-2581
37. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95(20):11709-11714
38. Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010;122(17):1725-1733
39. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci USA 2008;105(1):282-287
40. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186(3):261-272
41. Yee HY, Paquet A, Dudoit S. Exploratory analysis for twocolor spotted microarray data. R package version 1.20.0, 2007
42. Simon R, Korn E, McShane L, Radmacher M, Wright G, Zhao Y. Design and analysis of DNA microarray investigations. New York: Springer, 2003
43. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121
44. Al Husseini A, Wijesinghe DS, Farkas A, Kraskauskas D, Drake J, Chalfant CE, et al. Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension. Am J Respir Crit Care Med 2013;187:A4631
45. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45(6):1239-1247
46. Seymour LW, Shoaibi MA, Martin A, Ahmed A, Elvin P, Kerr DJ, et al. Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells. Lab Invest 1996;75(3):427-437
47. Cho CH, Lee CS, Chang M, Jang IH, Kim SJ, Hwang I, et al. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am J Physiol Heart Circ Physiol 2004;286(5):H1881-H1888
48. Ozaki K, Nagata M, Suzuki M, Fujiwara T, Ueda K, Miyoshi Y, et al. Isolation and characterization of a novel human lung-specific gene homologous to lysosomal membrane glycoproteins 1 and 2: significantly increased expression in cancers of various tissues. Cancer Res 1998;58(16):3499-3503
49. Kanao H, Enomoto T, Kimura T, Fujita M, Nakashima R, Ueda Y, et al. Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res 2005;65(19):8640-8645
50. Kobayashi T, Vischer UM, Rosnoblet C, Lebrand C, Lindsay M, Parton RG, et al. The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell 2000;11(5):1829-1843
51. Nagelkerke A, Mujcic H, Bussink J, Wouters BG, van Laarhoven HW, Sweep FC, et al. Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer 2011;117(16):3670-3681
52. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998;273(45):29635-29640
53. Chandrasekaran V, Ambati J, Ambati BK, Taylor EW. Molecular docking and analysis of interactions between vas- cular endothelial growth factor (VEGF) and SPARC protein. J Mol Graph Model 2007;26(4):775-782
54. Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGFA. J Clin Invest 2006;116(2):422-429
55. Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, et al. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 2001;287 (2):422-426
56. Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011;68 (19):3165-3173
57. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121(18):2045-2066
58. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012;126(22):2601-2611
59. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000;275(7):5096-5103
60. Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34 þ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J 2007;21(13):3640-3652
61. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med 2013;5(208):208sr5
62. Das JK, Voelkel NF, Felty Q. Overexpression of ID3 promotes a stem-like molecular signature in human endothelial cells: it’s implications in the development of hyperproliferative endothelial lesions associated with pulmonary hypertension. Pulm Circ (forthcoming)
63. Leclers D, Durand K, Cook-Moreau J, Rabinovitch-Chable H, Sturtz FG, Rigaud M. VEGFR-3, VEGF-C and VEGF-D mRNA quantification by RT-PCR in different human cell types. Anticancer Res 2006;26(3):1885-1891
64. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004;10(8):813-815
65. Yang J, Li X, Li Y, Southwood M, Ye L, Long L, et al. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2013;305(4):L312-L321
66. Min Y, Ghose S, Boelte K, Li J, Yang L, Lin PC. C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene 2011;30(49):4901-4909
67. Zhang JL, Chen GW, Liu YC, Wang PY, Wang X, Wan YL, et al. Secreted protein acidic and rich in cysteine (SPARC) suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer. PloS ONE 2012;7 (9):e44618
68. Gomez-Cambronero J. Phosphatidic acid, phospholipase D and tumorigenesis. Adv Biol Regul 2014;54:197-206
69. Alitalo K. The lymphatic vasculature in disease. Nat Med 2011;17(11):1371-1380
70. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008;358(2):199-200
71. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464(7290): 917-921
72. Serpi R, Tolonen AM, Huusko J, Rysa J, Tenhunen O, Yla- Herttuala S, et al. Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. Cardiovasc Res 2011;89(1):204-213
73. Kaza E, Ablasser K, Poutias D, Griffiths ER, Saad FA, Hofstaetter JG, et al. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res 2011;89(2):410-418
74. Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 2013;3(2): 369-380.